Enliven Therapeutics (ELVN) Projected to Post Earnings on Thursday

Enliven Therapeutics (NASDAQ:ELVN) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $0.0080 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 3:00 PM ET.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN opened at $29.98 on Thursday. The firm’s 50 day simple moving average is $24.80 and its 200-day simple moving average is $21.74. Enliven Therapeutics has a one year low of $13.30 and a one year high of $30.63. The firm has a market cap of $1.78 billion, a PE ratio of -16.12 and a beta of 0.33.

Insider Activity at Enliven Therapeutics

In other news, COO Anish Patel sold 48,300 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.99, for a total value of $1,351,917.00. Following the transaction, the chief operating officer owned 215,011 shares of the company’s stock, valued at $6,018,157.89. The trade was a 18.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard A. Heyman sold 1,230 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total transaction of $32,201.40. Following the transaction, the director owned 22,647 shares of the company’s stock, valued at approximately $592,898.46. This trade represents a 5.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 233,843 shares of company stock valued at $6,145,489 over the last quarter. 25.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ELVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Enliven Therapeutics by 10.6% in the 3rd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,529 shares of the company’s stock valued at $400,000 after purchasing an additional 1,873 shares during the period. Invesco Ltd. raised its position in shares of Enliven Therapeutics by 7.0% in the fourth quarter. Invesco Ltd. now owns 24,720 shares of the company’s stock worth $381,000 after acquiring an additional 1,624 shares during the period. WINTON GROUP Ltd purchased a new stake in shares of Enliven Therapeutics during the 3rd quarter worth about $337,000. Man Group plc acquired a new stake in shares of Enliven Therapeutics during the 3rd quarter valued at about $274,000. Finally, Intech Investment Management LLC grew its position in shares of Enliven Therapeutics by 15.6% during the 4th quarter. Intech Investment Management LLC now owns 16,729 shares of the company’s stock valued at $258,000 after acquiring an additional 2,256 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ELVN shares. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Enliven Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.00.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.